Biotech | August 17, 2022
Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
Collaboration supports multiple discovery efforts, including vaccines
Collaboration supports multiple discovery efforts, including vaccines
Site Enhances New Modality CRDMO Platform Capacity for Customers
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Both companies have been selected for stand-by production by German government
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
The transaction is expected to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
